The RDA during pregnancy is 1.4 mg/day and the RDA for lactating females is 1.6 mg/day
Siddiqi S, Mahan J, Siddiqi S, Gorelick F, Mansbach C 2nd
Recent progress and advances in stimuli-responsive polymers for cancer therapy
B Mater
Embodiment 8 of this disclosure are compounds of Formula I, or any one of Embodiments 1-7 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 Embodiment 9 of this disclosure are compounds of Formula I, or any one of Embodiments 1-8 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 28 of this disclosure are compounds of Formula I, or Embodiments 1-12, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 29 of this disclosure are compounds of Formula I, or Embodiments 1-11, 13, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 30 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 31 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 32 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 33 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 34 of this disclosure are compounds of Formula I, or Embodiments 1-11, 14, or 27, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is Embodiment 35 of this disclosure are compounds of Formula I, or any one of Embodiments 1-34, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 48 of this disclosure are compounds of Formula I, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 49 of this disclosure are compounds of Formula I, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 50 of this disclosure are compounds of Formula I, I-a, or I-b, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 51 of this disclosure are compounds of Formula I, I-a, or I-b, or any one of Embodiments 1-38 or 47, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is Embodiment 52 of this disclosure are compounds of Formula I, I-a, or I-b, or Embodiments 1-51, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is H
Therefore, there is still a need to improve existing prevention and control strategies, mainly focusing on developing novel vaccines and drugs, expediting medical authorization processes, and keeping epidemic surveillance
